Sector News

Johnson & Johnson Seeks Acquisitions in China

November 10, 2014
Life sciences
Johnson & Johnson is seeking acquisitions and aiming to expand in China despite facing a variety of challenges there, including a slowdown in the country’s economy.
 
Johnson & Johnson, which makes everything from prescription drugs and medical devices to Band-Aids and Listerine mouthwash, wants to boost its pharmaceutical sales in China by zeroing in on treatment for highly prevalent diseases, such as lung cancer, Chief Executive Alex Gorsky said in an interview with The Wall Street Journal on Monday. Medical devices accounted for half of the New Brunswick, N.J.-based company’s roughly $3 billion in China sales last year, which jumped 10% from 2012, Mr. Gorsky said. He said that pharmaceutical and consumer product sales are evenly split.
 
“One of the things we are concerned about is the drug lag you see,” Mr. Gorsky said, noting that it takes an average of eight years for drug approval in China, compared with four years in other markets. J&J is also eyeing Chinese companies to add to its portfolio of baby and beauty products, medical devices and drugs, Mr. Gorsky said on the sidelines of the Asia-Pacific Economic Cooperation CEO Summit.
 
Johnson & Johnson, an early entrant in the China market, has faced stiff competition there in recent years, as local and international rivals have piled in to sell baby products and medical devices. Challenges, such as piracy and patent protection, have created setbacks. The Chinese economy is also facing a slowdown.
 
J&J was among a number of contact-lens companies that were fined more than 19 million yuan ($3 million) in May for price-fixing in China’s eyeglass and contact lens market. J&J was fined 3.6 million yuan.
 
Mr. Gorsky said the company prioritizes “competing in an appropriate manner” and is doing its best to work with the government “to ensure a level playing field” under a common set of standards.
 
There are some cases in which J&J doesn’t face fair competition in China, Mr. Gorsky said. When asked to elaborate, he would only say “we support government actions in creating a leveled playing field for all companies.”
 
While China’s overall growth is slowing, access to health care has increased, Mr. Gorsky said, adding that J&J also sees opportunities for serving China’s aging population and treating noncommunicable diseases.
 
By Laurie Burkitt
 

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).